Gilead says Veklury should work against COVID-19 variants
pharmaphorum
JANUARY 22, 2021
According to the US biopharma company, genetic analyses of publicly available sequences for the new variants of SARS-CoV-2 suggest the mutations in the viral spike protein that have made them more transmissible shouldn’t affect the way Veklury (remdesivir) works. The UK strain – known as B.1.1.7
Let's personalize your content